Interferon-α for TP53 Myeloid Malignancy Post Allo-HSCT

PHASE2RecruitingINTERVENTIONAL
Enrollment

35

Participants

Timeline

Start Date

January 1, 2024

Primary Completion Date

December 31, 2025

Study Completion Date

June 30, 2026

Conditions
Myeloid LeukemiaMyelodysplastic Syndromes
Interventions
DRUG

IFN-Α

Leukemia-associated immunophenotyping (LAIPs) was performed by flow cytometry at +1 month and +2 month after HSCT. If MRD was negative on two consecutive flow cytometry assays, interferon-α prophylaxis was initiated on day +75 after transplantation, and cyclosporine was tapered on day +100 after transplantation. The dose of interferon-α was 3 million units/time, subcutaneously injected twice a week. Cycles were given every 4 weeks until hematologic relapse or up to 6 cycles.

Trial Locations (1)

100044

RECRUITING

Deparment of Hematology, Peking University People's Hospital, Beijing

All Listed Sponsors
lead

Peking University People's Hospital

OTHER